Kraków's J-PET Group and 21 Co-Authors Publish a Roadmap for Quantum Entanglement PET: What arXiv 2607.12182 and the June 2026 First-in-Human Scan Show
Quentir Medicine Monitor
Evidence-based insights for quantum medicine. Published by Quentir Systems LLC · September 29, 2026.
Every PET scan starts with a positron meeting an electron inside the patient. The two annihilate and send out a pair of gamma photons in opposite directions, and the scanner finds the tracer by catching both photons at once. Those photon pairs also carry a quantum property that no clinical scanner reads today: their polarizations are entangled. A group of physicists and imaging engineers now argues that this unused signal could sharpen PET images and add new diagnostic readings.
Their case is set out in "Roadmap Towards Quantum Entanglement Positron Emission Tomography (QE-PET)" (arXiv 2607.12182), posted on 13 July 2026 by 22 authors led by Paweł Moskal of the Jagiellonian University in Kraków, with teams from the University of California Santa Cruz, IIT Bombay, the University of Tokyo, the University of Sydney, the University of Zagreb, Japan's National Institutes for Quantum Science and Technology and others. The roadmap surveys how quantum entanglement PET could be built, from the plastic-scintillator J-PET scanner in Kraków to crystal, semiconductor and Compton-camera designs. It also describes a new candidate biomarker, the degree of quantum entanglement of the photon pair, which may depend on the tissue in which the positron annihilated.
Two experimental findings from the past three years made the idea worth pursuing. In 2023 an experiment showed that the quantum correlation between the two photons survives when one of them scatters off an electron, which most physicists had expected to destroy it. In 2025 the Kraków group reported in Science Advances that photons from annihilation in matter are less than maximally entangled, and that the degree of entanglement depends on how the annihilation happened. If that dependence tracks the chemistry of tissue, such as oxygen content, a scanner could read it as a new measurement alongside the usual tracer uptake.
A companion preprint makes the idea concrete. On 28 June 2026 the Kraków team and colleagues posted "First-in-human quantum entanglement imaging" (arXiv 2606.29421), reporting that the J-PET scanner produced, in one patient, both an image of a gallium-68 DOTA-TATE tracer and, from the same research acquisition, an image of the degree of entanglement. The roadmap reads that scan as a start. The authors state plainly that whether entanglement-based imaging and pH mapping can reach clinical practice "remains an open question."
What PET scanners discard today, and why photon polarization could help
A PET scanner decides that two detected photons belong together if they arrive within a few nanoseconds of each other and carry roughly the right energy. The roadmap cites typical clinical settings of about 4.5 to 6.9 nanoseconds for the time window and 430 to 645 keV for the energy window. These filters are imperfect. In a clinical scan, the authors write, a scatter fraction of about 37 percent remains after filtering, and accidental coincidences, where the two photons come from two different annihilations, often exceed 25 percent depending on the injected activity. Both effects blur the image and lower contrast.
Polarization offers a way to tell true pairs from accidental ones. Photons from the same annihilation share an entangled polarization state, so the planes in which they scatter inside the detector are correlated in a predictable way. Photons from two separate annihilations show no such correlation. A scanner that measures the scattering planes of both photons could, in principle, weight or reject events by how well they match the pattern expected of a true pair. That is the first of the three goals the roadmap lists: suppress random coincidences and improve the standard tracer image.
Doing this requires detectors that record where each photon scatters, which is why plastic scintillators matter. In plastic, 511 keV photons interact mainly through Compton scattering, and each scatter reveals information about the polarization plane. Crystal detectors in most hospital scanners absorb many photons through the photoelectric effect, which erases that information. The cost is sensitivity: plastic has a low atomic number, so fewer photons interact at all, and a quantum-correlation measurement needs both photons to scatter and then be detected again, a fourfold coincidence. The authors name this low sensitivity as the main barrier to clinical QE-PET.
Quantum pillar: sensing. Technology readiness: TRL 4 of 9. Laboratory prototypes can measure photon entanglement, and one first-in-human scan has produced an entanglement image, but no study has yet shown that the reading separates healthy from diseased tissue or changes any clinical decision.
How the Kraków J-PET group and partners in Tokyo, Sydney and Santa Cruz plan to build QE-PET scanners
The roadmap is organized as fifteen short chapters, each written by the group working on one detector route or one piece of physics. The J-PET chapter describes the modular prototype built from long plastic strips, with a coincidence resolving time of about 460 picoseconds, and a planned total-body version expected to reach about 3.7 to 4.9 millimeter spatial resolution and about 240 picoseconds timing. Other chapters cover crystal detectors such as LYSO and GAGG, cadmium zinc telluride semiconductors, whole-gamma imaging from Japan's National Institutes for Quantum Science and Technology, and combined PET and Compton-camera systems.
Scale is the practical lever. The roadmap points to total-body scanners such as EXPLORER and PennPET, whose one-to-two-meter axial fields of view raise detection sensitivity by up to forty times compared with conventional PET. More detected pairs mean more of the rare fourfold events a quantum measurement needs. For a hospital, this ties QE-PET to a class of scanners that only a few centers operate today, and to a plastic-detector design that the Kraków group presents as a lower-cost route to total-body coverage.
The roadmap also covers two related ideas. One uses positronium, a short-lived bound state of an electron and a positron, whose lifetime in tissue is sensitive to oxygen and is being studied as a hypoxia biomarker. Low oxygen in tumors is linked to resistance to radiotherapy, so a non-invasive oxygen reading would matter to oncologists. The other, from Mizuki Uenomachi of the Institute of Science Tokyo and Kenji Shimazoe of the University of Tokyo, uses perturbed angular correlation of gamma rays from nuclides such as indium-111 to sense the chemical surroundings of the tracer, with pH as the first target.
What the June 2026 first-in-human entanglement scan shows about liver and spleen
The first-in-human preprint reports one patient, a 48-year-old man who received 145 MBq of gallium-68 DOTA-TATE. After his routine diagnostic scan on a GE PET/CT system was complete, he had a separate 20-minute research acquisition on J-PET, starting 90 minutes after injection. From that acquisition the team reconstructed the tracer distribution and derived the degree of entanglement from the relative angle between the photons' scattering planes. The organ-wise estimates for the liver and spleen were 0.79 ± 0.21 and 0.76 ± 0.23. Their central values sit below the prediction for maximally entangled photon pairs and above the value expected for separable, non-entangled pairs, though the uncertainties are wide for a single patient. The direction matches the 2025 laboratory finding that entanglement in matter is not maximal.
A clinician should read this as a feasibility result. It shows that a prototype scanner can extract the measurement from a living person who has received a standard clinical tracer, in an extra research scan after the routine one, and report it organ by organ. It does not show that the measurement differs between healthy and diseased tissue, how much tracer activity or scan time a reliable reading needs, or how repeatable it is from one scan to the next. The roadmap itself names these gaps: the behavior of polarization correlation in biological tissue "has yet to be determined," and turning the readings into biomarkers that distinguish healthy from diseased tissue "requires further exploration and validation."
This is the same test this Monitor applied to the metabolic MRI installation planned at Yonsei University: a quantum-sensing method becomes medical infrastructure only when its signal is reproducible outside the group that invented it. QE-PET has an advantage there, because it builds on an existing clinical workflow. The patient receives a standard clinical tracer, and the entanglement image comes from the same detected photons as the uptake image, although in the first-in-human study both came from an additional research acquisition on the J-PET prototype.
Which three questions hospital imaging departments can put to QE-PET developers now
For a nuclear medicine department or a hospital buyer, three questions follow from the roadmap. The first is sensitivity: whether a total-body plastic or hybrid scanner can collect enough fourfold events in a normal scan time and dose to produce a stable entanglement image. The second is meaning: whether the degree of entanglement, or the positronium lifetime, tracks tumor oxygenation or other pathology in patient cohorts, with biopsy or established imaging as the reference. The third is integration: the roadmap lists compatibility with existing clinical workflows and other imaging modalities as a practical challenge still ahead.
None of these questions is answered yet, and the authors do not claim otherwise. What the roadmap supplies is a shared map of the detector routes, the physics that still needs settling, and the international groups working on each part. For readers following quantum medicine, QE-PET stands out because the quantum effect is a property of the photons every PET scan already produces. The next milestone to watch is a multi-patient study that compares entanglement readings between tissue types with a clinical reference measurement.
Sources
Primary source: Paweł Moskal (Jagiellonian University, Kraków) and 21 co-authors including Shiva Abbaszadeh, Zdenka Kuncic, Mihael Makek, Kenji Shimazoe, Mizuki Uenomachi and Taiga Yamaya, "Roadmap Towards Quantum Entanglement Positron Emission Tomography (QE-PET)," arXiv preprint 2607.12182, 13 July 2026, not yet peer reviewed. Also drawn on: the first-in-human quantum entanglement imaging preprint by Moskal and colleagues (arXiv 2606.29421, 28 June 2026) and the group's 2025 Science Advances paper on non-maximal entanglement; the readiness assessment is this Monitor's own.